Form 8-K - Current report:
SEC Accession No. 0001837607-24-000026
Filing Date
2024-04-15
Accepted
2024-04-15 16:16:11
Documents
16
Period of Report
2024-04-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20240415x8k.htm   iXBRL 8-K 46026
2 EX-99.1 aeon-20240415xex99d1.htm EX-99.1 8135
  Complete submission text file 0001837607-24-000026.txt   246307

Data Files

Seq Description Document Type Size
3 EX-101.SCH aeon-20240415.xsd EX-101.SCH 4361
4 EX-101.DEF aeon-20240415_def.xml EX-101.DEF 14402
5 EX-101.LAB aeon-20240415_lab.xml EX-101.LAB 16785
6 EX-101.PRE aeon-20240415_pre.xml EX-101.PRE 14790
19 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240415x8k_htm.xml XML 7177
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 24844828
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)